Gilead Sciences, Inc. (GILD) recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the prevention of HIV. Data reinforce that twice-yearly lenacapavir could be a highly effective and potentially game-changing HIV prevention option. Additional Data From GILD's HIV Study The double-blind, multicenter, randomized study phase III study, PURPOSE 2, is evaluating the safety and efficacy of twice-yearly su ...

In the latest market close, Gilead Sciences (GILD) reached $85.21, with a +0.92% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.97%. Meanwhile, the Dow experienced a rise of 0.3%, and the technology-dominated Nasdaq saw an increase of 1.45%.Heading into today, shares of the HIV and hepatitis C drugmaker had gained 6.64% over the past month, outpacing the Medical sector's loss of 3.72% and the S&P 500's gain of 5.41% in that time.Analysts and investors ...

In the long term, Gilead's (NASDAQ: GILD ) top and bottom lines should be meaningfully lifted by its lenacapavir drug which has been shown to prevent nearly all HIV transmission and could become a blockbuster for the firm. AndAnalyst’s Disclosure: I/we have a beneficial long position in the shares of GSK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have n ...

Gilead Sciences (GILD) has entered into licensing deals with six pharmaceutical companies to manufacture and supply a cheaper version of its investigational drug, lenacapavir, for HIV prevention, also called pre-exposure prophylaxis (PrEP). These companies will market the low-cost versions of lenacapavir, if approved, in 120 primarily low-and-lower-middle-income countries.The companies chosen to manufacture and supply lenacapavir to 120 countries are Dr. Reddy’s Laboratories, Emcure, Eva Pharma, Ferozsons L ...

Gilead Sciences (GILD) closed the latest trading day at $83.79, indicating a -0.24% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.25%. On the other hand, the Dow registered a gain of 0.2%, and the technology-centric Nasdaq increased by 0.56%.The the stock of HIV and hepatitis C drugmaker has risen by 9.13% in the past month, leading the Medical sector's loss of 1.51% and the S&P 500's gain of 1.65%.The investment community will be closely monitoring t ...

Gilead Sciences, Inc. (GILD) announced upbeat results from an interim analysis of a second late-stage study evaluating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV.Results showed that lenacapavir, administered twice yearly, not only reduced HIV infections by 96% but also demonstrated superiority to Gilead’s daily HIV pill Truvada.The strong results validated lenacapavir’s potential to prevent HIV. Investors were impressed and GILD stock was ...

In drug development, solid performance in large-scale clinical trials is crucial.There was some good news in the clinical sphere for Gilead Sciences (GILD 2.74%) on Thursday, and this drove its stock price up by almost 3% that trading session. A late-stage clinical trial of an investigational drug yielded encouraging initial results, hence the rise. In comparison, the S&P 500 index inched up by 0.8% on the day.HIV drug does well in the labGilead's news was that its second phase 3 trial of HIV drug lenacapav ...

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday.The positive phase three trial data on Lenacapavir sets the stage for likely approval by the U.S. Food and Drug Administration for HIV prevention."Now that we have a comprehensive dataset across multiple study populations, Gilead will work urgently with regulatory, government, public health and community partners to ensure that, if approved, we can deliver twice-yearly lenacapavir for PrEP worldwide, ...

Gilead Sciences, Inc. (NASDAQ:GILD) Baird Global Healthcare Conference September 10, 2024 10:50 PM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Skorney - Baird Brian Skorney [Starts abruptly] biotech analysts here. [Technical Difficulty] to have presenting with us next, Gilead Sciences. Thanks for coming today. We really appreciate it. Maybe just to kick things off, I'll kind of ask the general question to give a broad overview of what Gilead does and ...

Gilead Sciences, Inc. (NASDAQ:GILD) Baird Global Healthcare Conference September 10, 2024 10:50 PM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Skorney - Baird Brian Skorney [Starts abruptly] biotech analysts here. [Technical Difficulty] to have presenting with us next, Gilead Sciences. Thanks for coming today. We really appreciate it. Maybe just to kick things off, I'll kind of ask the general question to give a broad overview of what Gilead does and ...